# Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

Source: https://onco.cc/trials/nct05422911/  
OnCo record `nct05422911` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Abiraterone acetate, Apalutamide, Enzalutamide in metastatic cancer and prostate cancer, run by Sun Pharmaceutical Industries Limited, now recruiting.

## Summary

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. is a phase 2 interventional study registered as NCT05422911 by Sun Pharmaceutical Industries Limited, with 192 participants planned, started 2022-08-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abiraterone acetate, Apalutamide, Enzalutamide. Conditions listed: Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05422911
- Phase: 2
- Setting: A Phase 2 Randomized Study of Abiraterone Acetate, Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer
- Sponsor: Sun Pharmaceutical Industries Limited
- Enrolled: 192

## Sources

- ClinicalTrials.gov NCT05422911: https://clinicaltrials.gov/study/NCT05422911

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Apalutamide](https://onco.cc/drugs/apalutamide/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/)
- companies: [Sun Pharmaceutical Industries](https://onco.cc/companies/sun-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05422911.json